21. Targeting What Others Miss: How HaemaLogiX Is Tackling Multiple Myeloma's Toughest Challenges

Описание: Multiple myeloma remains the second-largest blood cancer globally with no cure, and despite recent breakthroughs in CAR-T and antibody therapies, patients continue to relapse, often losing the very antigens that therapies target. In this episode of BioBiz Buzz, host Mike Ward speaks with Dr. Chris Baldwin, CEO and Managing Director of HaemaLogiX, an Australian clinical-stage biotech pioneering a differentiated approach to treating this devastating disease.


HaemaLogiX has identified two novel antigens, kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), that are uniquely expressed on malignant plasma cells but absent from healthy immune cells, offering exquisite tumor specificity. The company's lead asset, KappaMab, has already demonstrated an 83% response rate and a 46% reduction in death risk in Phase IIb trials, while its KMA.CAR-T therapy is progressing through Phase 1 trials in partnership with the renowned Peter MacCallum Cancer Centre.


Dr. Baldwin discusses the significant unmet medical need in multiple myeloma,  where median survival post-diagnosis is just five to seven years and treatment-related toxicities often devastate patients' immune systems. He explains how HaemaLogiX's approach addresses critical limitations of current BCMA-targeted therapies, including antigen loss at relapse, off-target toxicity, and immune suppression. With approximately 70% of myeloma patients expressing KMA and the remaining 30% expressing LMA, HaemaLogiX's platform could potentially treat nearly all multiple myeloma patients.


Looking ahead to the company's planned ASX IPO in 2026, Dr. Baldwin outlines the strategic priorities: advancing the higher-dose Phase IIb trial of KappaMab in combination with standard-of-care therapies, enrolling and treating patients in the Peter Mac CAR-T trial, developing LambdaMab for lambda-type myeloma and AL amyloidosis, and expanding into next-generation bispecific antibodies. He also addresses the operational challenges of scaling CAR-T manufacturing, navigating competitive dynamics in the crowded immunotherapy landscape, and securing the capital needed to bring these life-saving therapies to market in a sector valued at over $23 billion annually and growing at 6-8% per year.


This conversation provides essential insights for investors, clinicians, and industry stakeholders seeking to understand how differentiated science, strategic partnerships, and disciplined clinical development can position an emerging biotech to address one of oncology's most intractable diseases. 


● Feedback (https://biobizbuzz.com/contact/)


● Subscribe (https://biobizbuzz.com/subscribe/) (Get notified when new episodes are available. NO marketing!)


● Disclaimer (https://biobizbuzz.com/disclaimer/)


● LinkedIn (  / biobizbuzz  )